Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
OPTI Medical Systems receives CE mark for OPTI SARS-CoV-2 RNA PCR test kit » 07:03
06/05/20
06/05
07:03
06/05/20
07:03
IDXX

Idexx Laboratories

$310.34 /

-8.06 (-2.53%)

OPTI Medical Systems, a…

OPTI Medical Systems, a subsidiary of IDEXX Laboratories, announced that it has received the CE mark certification in the European Union for its OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France as well as Emergency Use Authorization by the United States FDA. Additionally, the FDA has granted EUA for the new OPTI DNA/RNA Magnetic Bead Kit for nucleic acid extraction from respiratory samples to be used with the OPTI SARS-CoV-2 RT-PCR test kit, which enables OPTI Medical Systems to provide laboratories with a complete OPTI Medical Systems-manufactured workflow solution for COVID-19 testing.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$310.34 /

-8.06 (-2.53%)

IDXX Idexx Laboratories
$310.34 /

-8.06 (-2.53%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
IDXX Idexx Laboratories
$310.34 /

-8.06 (-2.53%)

IDXX Idexx Laboratories
$310.34 /

-8.06 (-2.53%)

On The Fly
Fly Intel: After-Hours Movers » 18:24
05/26/20
05/26
18:24
05/26/20
18:24
STNE

StoneCo

$26.60 /

+2.14 (+8.75%)

, OOMA

Ooma

$13.47 /

+1.21 (+9.87%)

, TSCO

Tractor Supply

$111.19 /

-0.73 (-0.65%)

, HEI

Heico

$99.69 /

+5.78 (+6.15%)

, CHRS

Coherus Biosciences

$16.96 /

-0.16 (-0.93%)

, ESNT

Essent Group

$32.66 /

+2.55 (+8.47%)

, PTEN

Patterson-UTI

$3.89 /

+0.315 (+8.82%)

, JACK

Jack in the Box

$65.31 /

-1.27 (-1.91%)

, IDXX

Idexx Laboratories

$290.39 /

-4.18 (-1.42%)

, BMY

Bristol-Myers

$60.33 /

-0.45 (-0.74%)

, VSAT

ViaSat

$47.79 /

+5.59 (+13.25%)

, KEYS

Keysight Technologies

$103.49 /

+1.345 (+1.32%)

, SBLK

Star Bulk Carriers

$5.29 /

+0.18 (+3.52%)

, RPAY

Repay Holdings

$21.97 /

-1.05 (-4.56%)

, FVRR

Fiverr

$62.10 /

+2.45 (+4.11%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

OOMA Ooma
$13.47 /

+1.21 (+9.87%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

05/19/20 Citi
StoneCo price target raised to $30 from $28 at Citi
03/31/20 Citi
StoneCo price target lowered to $28 from $50 at Citi
03/27/20 HSBC
StoneCo upgraded to Hold from Reduce at HSBC
03/03/20 Cantor Fitzgerald
StoneCo price target raised to $49 from $40 at Cantor Fitzgerald
OOMA Ooma
$13.47 /

+1.21 (+9.87%)

03/16/20
Fly Intel: Top five analyst initiations
03/16/20 Alliance Global Partners
Ooma initiated with a Buy at Alliance Global Partners
09/30/19 BofA
BofA/Merrill downgrades Ooma to Underperform, sees re-acceleration as unlikely
09/30/19 BofA
Ooma downgraded to Underperform from Neutral at BofA/Merrill
TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

05/19/20 Northcoast
Tractor Supply downgraded to Neutral from Buy at Northcoast
04/23/20 Baird
Tractor Supply price target raised to $115 from $105 at Baird
04/23/20 Baird
Tractor Supply Q2 off to 'strong start,' says Baird
04/15/20 Wedbush
Tractor Supply downgraded to Neutral at Wedbush as optimism priced in
HEI Heico
$99.69 /

+5.78 (+6.15%)

05/18/20 Canaccord
Heico downgraded to Hold at Canaccord
05/18/20 Canaccord
Heico downgraded to Hold from Buy at Canaccord
03/31/20 Jefferies
Heico downgraded to Hold from Buy at Jefferies
03/30/20 Vertical Research
Heico downgraded to Hold from Buy at Vertical Research
CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

04/17/20 SunTrust
Coherus Biosciences initiated with a Buy at SunTrust
04/17/20 SunTrust
Coherus Biosciences initiated with a Buy at SunTrust
04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
02/05/20 Mizuho
Mizuho sees 'immaterial' impact on Coherus shares from BLA withdrawal
ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

05/12/20 Deutsche Bank
Essent Group price target lowered to $47 from $58 at Deutsche Bank
03/26/20 MKM Partners
MKM Partners sees Mortgage Insurers as attractively valued
03/26/20 RBC Capital
Essent Group price target lowered to $36 from $62 at RBC Capital
03/11/20 MKM Partners
Essent Group upgraded to Buy from Neutral at MKM Partners
PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

04/27/20 Gabelli
Patterson-UTI downgraded to Hold from Buy at Gabelli
04/14/20 Cowen
Patterson-UTI downgraded to Market Perform at Cowen
04/14/20 Cowen
Patterson-UTI downgraded to Market Perform from Outperform at Cowen
04/05/20 Bernstein
Patterson-UTI upgraded to Market Perform from Underperform at Bernstein
JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/15/20 SunTrust
Jack in the Box price target raised to $86 from $79 at SunTrust
05/15/20 Cowen
Jack in the Box price target raised to $68 from $42 at Cowen
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

05/20/20 William Blair
ViaSat defense contract renewal positive for shares, says William Blair
04/20/20 Barclays
Barclays upgrades ViaSat to Equal Weight on more balanced risk/reward
04/20/20 Barclays
ViaSat upgraded to Equal Weight from Underweight at Barclays
03/13/20 William Blair
Delta dual sourcing Wi-Fi potentially positive for ViaSat, says William Blair
KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

04/14/20 JPMorgan
Keysight Technologies initiated with a Neutral at JPMorgan
03/18/20 Stifel
Keysight demand should remain healthy post-crisis, says Stifel
03/04/20 Citi
Keysight 'best and most agnostic way' to play 5G, says Citi
02/25/20 Deutsche Bank
Keysight Technologies price target raised to $130 from $125 at Deutsche Bank
SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

03/09/20 DNB Markets
Star Bulk Carriers downgraded to Hold from Buy at DNB Markets
02/20/20 Fearnley
Star Bulk Carriers upgraded to Buy from Hold at Fearnley
01/27/20 Fearnley
Star Bulk Carriers downgraded to Hold from Buy at Fearnley
11/13/19 Pareto
Star Bulk Carriers downgraded to Hold from Buy at Pareto
RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

05/19/20 BTIG
Repay Holdings price target raised to $25 from $20 at BTIG
04/17/20
Fly Intel: Top five analyst initiations
04/17/20 DA Davidson
Repay Holdings initiated with a Buy at DA Davidson
03/17/20 Canaccord
Repay Holdings outlook could be helped by current environment, says Canaccord
FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

05/08/20 JPMorgan
Fiverr price target raised to $54 from $37 at JPMorgan
02/21/20
Fiverr management to meet with Oppenheimer
02/20/20
Fly Intel: Top five analyst upgrades
02/20/20 JPMorgan
Fiverr upgraded to Overweight with $37 price target at JPMorgan
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

OOMA Ooma
$13.47 /

+1.21 (+9.87%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

  • 29
    May
  • 29
    May
PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

Hot Stocks
Idexx Laboratories sees 'meaningful improvement in U.S. clinical visit trends' » 17:02
05/26/20
05/26
17:02
05/26/20
17:02
IDXX

Idexx Laboratories

$290.39 /

-4.18 (-1.42%)

Idexx Laboratories…

Idexx Laboratories provided an update on U.S. Companion Animal Market Trends through Friday, May 22nd. "We are monitoring the impact of the COVID-19 pandemic on U.S. companion animal practice visit trends, including the effect of stay-at-home and social distancing policies to prevent the spread of COVID-19, as well as the related prioritization of sick and emergency testing at veterinary clinics. With an additional four weeks of activity since our last update, we continue to see meaningful improvement in U.S. clinical visit trends across major regions, with overall U.S. clinical visits, non-wellness visits and wellness visits surpassing prior year levels in the most recent week ended May 22nd."

ShowHide Related Items >><<
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

Hot Stocks
OPTI Medical receives FDA EUA for OPTI SARS-CoV-2 RNA PCR test kit » 07:38
05/07/20
05/07
07:38
05/07/20
07:38
IDXX

Idexx Laboratories

$283.47 /

+1.45 (+0.51%)

OPTI Medical Systems, a…

OPTI Medical Systems, a subsidiary of IDEXX Laboratories, announced that the United States FDA has granted Emergency Use Authorization for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$283.47 /

+1.45 (+0.51%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
Hot Stocks
Idexx Laboratories announces business update amid COVID-19 pandemic » 06:46
04/30/20
04/30
06:46
04/30/20
06:46
IDXX

Idexx Laboratories

$273.04 /

+8.64 (+3.27%)

The primary impacts of…

The primary impacts of the COVID-19 pandemic have been seen in Idexx's CAG business. While veterinary care is widely recognized as an "essential" service for pet owners, and veterinarians continue to deliver essential medical care for sick and injured pets, stay-at-home and social distancing policies being deployed to combat the spread of COVID-19, and prioritization of sick and emergency testing at veterinary clinics, have resulted in a decrease in companion animal clinical visits, including delay of elective procedures and wellness visits. These types of trends have contributed to year-over-year declines in demand for Idexx's products and services during this period, with varying impacts by region and diagnostic testing modality. These impacts are dynamic, and the company has seen meaningful improvement in clinical visit and diagnostic testing trends over the most recent two-week period ended April 24, driven by U.S. and International regions where COVID-19 case management efforts have progressed further and where stay-at-home and social distancing policies have been moderated.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$273.04 /

+8.64 (+3.27%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
Earnings
Idexx Laboratories withdraws FY20 guidance amid COVID-19 unpredictability » 06:44
04/30/20
04/30
06:44
04/30/20
06:44
IDXX

Idexx Laboratories

$273.04 /

+8.64 (+3.27%)

The company is…

The company is withdrawing its previously announced FY20 guidance due to the unpredictability of the duration and the magnitude of impacts from the COVID-19 pandemic on veterinary service providers.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$273.04 /

+8.64 (+3.27%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
Earnings
Idexx Laboratories reports Q1 EPS $1.29, consensus $1.20 » 06:43
04/30/20
04/30
06:43
04/30/20
06:43
IDXX

Idexx Laboratories

$273.04 /

+8.64 (+3.27%)

Reports Q1 revenue…

Reports Q1 revenue $626.34M, consensus $617.41M. "We are pleased to report excellent first quarter financial results, supported by continued double-digit organic gains in CAG Diagnostics recurring revenues, despite late-quarter impacts from the expansion of COVID-19-related stay-at-home policies and social distancing procedures. These results reflect continued strong underlying demand globally for companion animal healthcare," said Jay Mazelsky, the company's president and CEO. "We have seen near-term impacts on veterinary practices related to the COVID-19 pandemic and have been closely monitoring the effect of social distancing policies and industry care guidelines on our customers. IDEXX has continued to provide high levels of service delivery and product support for its customers during this time, while advancing key steps to protect the safety and health of its employees, ensure business continuity and mitigate the near-term impacts on demand for IDEXX products and services. The pet-owner bond is stronger than ever, and IDEXX's strategy, opportunity and fundamentals remain intact, supported by our innovative product portfolio and talented global team. We are very well-positioned for a strong recovery in the highly attractive and resilient companion animal healthcare market. I am extremely proud of the way our team is working together to respond during this time and thank them for their extraordinary commitment to our Purpose."

ShowHide Related Items >><<
IDXX Idexx Laboratories
$273.04 /

+8.64 (+3.27%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
Recommendations
Idexx Laboratories checks on placements look soft, says Cleveland Research » 09:30
04/27/20
04/27
09:30
04/27/20
09:30
IDXX

Idexx Laboratories

$271.59 /

+3.54 (+1.32%)

Cleveland Research…

Cleveland Research analyst Rob Eich said his checks suggests Idexx in-lab diagnostic equipment placements were soft at the end of Q1 and continue to be weak in April due to COVID-19. He believes placements will take several quarters to return to growth and thinks that visits likely remaining pressured for the foreseeable future will continue to impact consumables, rapid assay, and reference lab growth. Eich keeps a Neutral rating on Idexx Laboratories shares.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$271.59 /

+3.54 (+1.32%)

03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
09/09/19 Goldman Sachs
Idexx Laboratories initiated with a Neutral at Goldman Sachs
Hot Stocks
Idexx Laboratories makes pet test for COVID-19 available to veterinarians » 07:39
04/20/20
04/20
07:39
04/20/20
07:39
IDXX

Idexx Laboratories

$265.21 /

+4.17 (+1.60%)

IDEXX Laboratories…

IDEXX Laboratories announced the availability of the IDEXX SARS-CoV-2 RealPCR Test for pets. IDEXX is launching the test in response to customer demand and growing evidence that in rare cases pets living with COVID-19 positive humans can be at risk for SARS-CoV-2 infection. The test will be available to veterinarians in North America this week and will continue to roll out across most of the world in the coming weeks, enabled by IDEXX Reference Laboratories, the company's worldwide network of more than 80 laboratories.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$265.21 /

+4.17 (+1.60%)

03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
09/09/19 Goldman Sachs
Idexx Laboratories initiated with a Neutral at Goldman Sachs
Over a quarter ago
Conference/Events
Stifel animal health analysts to hold an analyst/industry conference call » 13:55
03/19/20
03/19
13:55
03/19/20
13:55
TRUP

Trupanion

$26.73 /

+0.67 (+2.57%)

, KIN

Kindred Biosciences

$5.20 /

+1.785 (+52.35%)

, CVT

Cvent

$0.00 /

+ (+0.00%)

, IDXX

Idexx Laboratories

$195.84 /

-10.15 (-4.93%)

, ZTS

Zoetis

$104.70 /

-1.33 (-1.25%)

Analysts discuss the…

Analysts discuss the Animal Health Industry and their expectations that there will be some impact to the industry growth in the 2Q20 due to COVID-19 on an Analyst/Industry conference call to be held on March 19 at 2:30 pm.

ShowHide Related Items >><<
TRUP Trupanion
$26.73 /

+0.67 (+2.57%)

02/14/20 Lake Street
Trupanion price target raised to $50 from $46 at Lake Street
02/14/20 Raymond James
Trupanion 'noise' limits near-term upside, says Raymond James
02/14/20 Raymond James
Trupanion downgraded to Market Perform from Outperform at Raymond James
01/09/20
Fly Intel: Top five analyst downgrades
KIN Kindred Biosciences
$5.20 /

+1.785 (+52.35%)

03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
06/11/19 Barclays
Kindred Biosciences initiated with an Overweight at Barclays
CVT Cvent
$0.00 /

+ (+0.00%)

IDXX Idexx Laboratories
$195.84 /

-10.15 (-4.93%)

03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
09/09/19 Goldman Sachs
Idexx Laboratories initiated with a Neutral at Goldman Sachs
ZTS Zoetis
$104.70 /

-1.33 (-1.25%)

02/14/20 SunTrust
Zoetis price target raised to $145 from $130 at SunTrust
01/10/20 Raymond James
Zoetis' premium valuation vs. peers likely to persist, says Raymond James
01/09/20 Raymond James
Zoetis initiated with a Market Perform at Raymond James

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.